- Reaction score
- 1,697
World-first clinical trials of a groundbreaking treatment for aggressive brain tumours are likely to begin soon following "fantastic" results in the high-profile case of Australian of the Year, Professor Richard Scolyer.
Professor Scolyer, 57, was diagnosed with glioblastoma IDH wild-type in early June last year and became "patient zero" in a pioneering immunotherapy approach that has produced remarkable results: the tumour has not come back after 10 months.
"I'm blown away," Professor Scolyer tells Australian Story. "This is not what I expected. The average time to recurrence for the nasty type of brain cancer I've got is six months. So, to be out this far is amazing. Amazing."
Now, work is underway developing protocols for the start of clinical trials. If the results of those trials are strong, it could shake-up the current treatment regimen of surgery, chemotherapy and radiation that has not changed in 19 years.
www.abc.net.au
Professor Scolyer, 57, was diagnosed with glioblastoma IDH wild-type in early June last year and became "patient zero" in a pioneering immunotherapy approach that has produced remarkable results: the tumour has not come back after 10 months.
"I'm blown away," Professor Scolyer tells Australian Story. "This is not what I expected. The average time to recurrence for the nasty type of brain cancer I've got is six months. So, to be out this far is amazing. Amazing."
Now, work is underway developing protocols for the start of clinical trials. If the results of those trials are strong, it could shake-up the current treatment regimen of surgery, chemotherapy and radiation that has not changed in 19 years.
World-first clinical trials soon to start after 'fantastic' results for Richard Scolyer
Professor Richard Scolyer took courageous steps as a cancer researcher, becoming a guinea pig for a radical experiment. And the results could spell the biggest breakthrough in 20 years.
www.abc.net.au
